4PWL image
Entry Detail
PDB ID:
4PWL
Keywords:
Title:
Crystal structure of the complex between PPARgamma-LBD and the S enantiomer of Mbx-102 (Metaglidasen)
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2014-03-20
Release Date:
2015-02-11
Method Details:
Experimental Method:
Resolution:
2.60 Å
R-Value Free:
0.30
R-Value Work:
0.21
R-Value Observed:
0.22
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Peroxisome proliferator-activated receptor gamma
Chain IDs:A, B
Chain Length:287
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles.
Chemmedchem 10 555 565 (2015)
PMID: 25641779 DOI: 10.1002/cmdc.201402462

Abstact

Metaglidasen is a fibrate-like drug reported as a selective modulator of peroxisome proliferator-activated receptor γ (PPARγ), able to lower plasma glucose levels in the absence of the side effects typically observed with thiazolidinedione antidiabetic agents in current use. Herein we report an improved synthesis of metaglidasen's metabolically active form halofenic acid (R)-2 and that of its enantiomer (S)-2. The activity of the two stereoisomers was carefully examined on PPARα and PPARγ subtypes. As expected, both showed partial agonist activity toward PPARγ; the investigation of PPARα activity, however, led to unexpected results. In particular, (S)-2 was found to act as a partial agonist, whereas (R)-2 behaved as an antagonist. X-ray crystallographic studies with PPARγ were carried out to gain more insight on the molecular-level interactions and to propose a binding mode. Given the adverse effects provoked by fibrate drugs on skeletal muscle function, we also investigated the capacity of (R)-2 and (S)-2 to block conductance of the skeletal muscle membrane chloride channel. The results showed a more beneficial profile for (R)-2, the activity of which on skeletal muscle function, however, should not be overlooked in the ongoing clinical trials studying its long-term effects.

Legend

Protein

Chemical

Disease

Primary Citation of related structures